Izotropic Marks Breast Cancer Awareness Month by Highlighting Gaps in Care and the Need for IzoView Breast CT – The Canadian Business Journal

Vancouver, British Colombia and Sacramento, California, October 8, 2025 (Globe Newswire) – Through IBN – Isotropic corporation (CSE: Those) (OTCQB: Izozf) (FSE: 1R3) (“Isotropic“, Or”Company“), The company for medical devices commercials innovative, new technologies and products based on visualization for more accurate screening, diagnosis and treatment of breast cancer, marks Month of awareness of breast cancer Emphasizing the constant restrictions in modern visualization of breast cancer and significant commercial and clinical capabilities for the flagship structure of the company, Izovevest Groud CT -Visualization SystemField

Problem and unsatisfied need

Breast cancer remains most often diagnosed with cancer among women around the world, and every year it is reported about more than 2.3 million new cases. In the United States alone, it is expected to be diagnosed with breast cancer in more than 315,000 cases, which is almost every third diagnosis of cancer in women. As more and more women enter the age range, which has the right, and the population continues age, the burden on healthcare systems and screening infrastructure intensifies. This growing burden of the disease corresponds to severe market growth forecasts for the technology of visualization of the mammary gland. General world market It is expected to grow From $ 5.4 billion in 2024 to $ 8.69 billion in 2030 (CAGR 8.25%).

There is a clear unsatisfied need for the true modalities of 3D-visualization with high resolution, especially for women with dense breast tissue, a characteristic characteristic of the patient, affecting approximately 50% of women who reduce the effectiveness of compression-based. Studies show that approximately 20% of breast cancer present during mammography screening, 10-12% of the screening return false negatives, and 50–60% of women can expect at least one false positive result after 10 years of annual screening, which contributes to unnecessary anxiety and evaluative $ 8 billion in the subsequent registered procedure and diagnostic procedure after initial mammography annually

In 2024, FDA provided a new mandate, which all American screening institutions inform women about their breast density with the results of mammography. Some states also require a statement recommending that women discuss the option of additional screening using ultrasound or MRI from a dense breast with their primary medical care clinicists.

The target group on the preventive services of the United States also released an urgent call to receive additional information about whether additional screening can help women with dense breasts find cancer earlier.

Restrictions on current methods

Mammography based on compression and DBT remain The main screening toolsBut their sensitivity is reduced in women with a dense breast tissue, where overlapping structures during compression can hide the lesions. While studies show that DBT has a higher sensitivity than digital mammography, it still produces false negatives, and women with extremely dense breasts are predisposed to missed cancer.

Ultrasound is often used as an additional tool in a dense chest, but it can bring high false positive speeds and depends on the operator. Automated ultrasonic devices are aimed at reducing dependence on the operator; Nevertheless, anomalies are still required by manual ultrasound, adding steps to the workflow. Mammography, enhanced by contrast, is a special system designed to compensate for 2D, based on compression of restrictions with contrast, but it cannot provide the same valuable clinical information as the true three -dimensional visualization.

The breast MRI is very sensitive as the current gold standard for visualization of the 3D breast, but it is expensive and time -consuming, and since it returns high false positive indicators, it is usually reserved for patients with high risk.

CT solution for the chest izoView

Izoveiew is a specialized system of images of CT breastsDesigned for launching with the original indicator for use for screening cancer of the mammary gland, complementing the digital tomosintez of the mammary gland in asymptomatic women with dense breast tissue. Waiting is fulfilled with a patient lying down down without compression of the mammary gland. The system receives approximately 500 images with high resolution in about 10 seconds (depending on the length of the chest) and reconstructs the true volume of 3D breast that radiologists can consider from any corner or by scrolling of the cross -section slices. IN Research trials It was shown that the CT technology, founded at the University of California in Davis and is licensed exclusively on isotropic, malignant masses, are more noticeable for contrasting CT than mammography and DBT, simultaneously offering spatial resolution by about 100 times more than an MRI. It is positioned to overcome the gap between DBT and MRI, as well as with The sale price of the target device is 500 thousand US dollarsIzoView can satisfy the unsatisfied need for advanced tools for visualization of breast cancer at a price intended to support adoption in a wide spectrum of visualization with various resource capabilities.

A month of awareness of breast cancer emphasizes that today's screening tools are still left up to important gaps, especially for women with dense breast tissue. Regulators and governing bodies direct attention to these problems, and the growing load on the screening infrastructure emphasizes the need for new approaches to visualization, which ensure true three -dimensional information without compression of the mammary gland. Isotropic sees a clear role for the breast CT dedicated to a more effective screening path.

This month, isotropic recognizes patients, families and clinicians affected by breast cancer, and confirms our commitment to the development of tools intended to ensure earlier detection and better care.

About izotropic:

More information about the Izotropic Corporation can be found on its corporate web. izocorp.comHis educational site in breastAnd, looking at your profile on the Sedra in Sedarplus.caField

Statements forward:
This document may contain statements that are “forecast statements” that are based on current assessments, assumptions, forecasts and expectations of management, the company's business and its knowledge about the relevant market and the economic environment in which it works. The company tried, where possible, to determine such information and statements using such words as “expectation”, “believe”, “foresight”, “evaluation”, “expect”, “intention”, “maybe”, “plan”, “predict”, “project”, “potential”, “potential”, “will”, “will,“ could, “continue”, “continue”, “continue” and “contemplation” and other statements, “contemplation” and other statements, As well as others, as well as others, as well as others, as well as other statements, as well as others – these are discussed ”and others, which is different – all that can be found in the future, and others are discussed” and others, that otherwise – all that can be found in the future, and in other cases. Trends or prospects or future operating or financial indicators, although not all statements about the future contain these identifying words.

These statements are not guarantees of efficiency and include risks, including those related to capital and uncertainty requirements that are difficult to control or predict, and, as such, they can lead to a significant distinction between future results of the company's activities and the consequences of such statements. The advanced statements are appropriate only on the date when they are made, and the company is not obliged to update or revise any forecast statements to reflect new information or the emergence of future events or circumstances, unless otherwise required for this by law. Neither the company nor its shareholders, officials and consultants are responsible for any actions and the results of any actions taken by any person based on the information contained in this document, including, among other things, the purchase or sale of securities of the company. Nothing in this document should be considered a medical or other advice of any kind. All images are intended only for illustrative purposes. IzoView has not yet been approved and not cleaned for sale.

Contacts:

Robert Tast, Provisional Executive Director
Phone: 1-604-220-5031 or 1-833 -izocorp ext. 1
E-mail: [email protected]

James Ganion, International Communication
Phone: 1-604-780-7576 or 1-833 -izocorp ext. 2
E-mail: [email protected]

General and corporate requests
Phone: 1-604-825-4778 or 1-833 -izocorp ext. 3
E-mail: [email protected]

Corporate communications
Ibn
Austin, Texas
www.investorbrandnetwork.com
512.354.7000 office
[email protected]

CBJ Newsmakers